Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-12-02T22:04:49.404Z Has data issue: false hasContentIssue false

Rifampin plus Metronidazole for Clostridium difficile Infection

Published online by Cambridge University Press:  02 January 2015

Dimitri M. Drekonja*
Affiliation:
Infectious Diseases Section, Minneapolis Veterans Affairs Medical Center, and the Department of Medicine, University of Minnesota, Minneapolis, Minnesota
*
Infectious Diseases (111F), Minneapolis VA Medical Center, 1 Veterans Drive, Minneapolis, MN 55417 ([email protected])
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2010

References

1.Cohen, SH, Gerding, DN, Johnson, S, et al.Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431455.Google Scholar
2.Lagrotteria, D, Holmes, S, Smieja, M, Smaili, F, Lee, C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:547552.Google Scholar
3.Aslam, S, Hamili, RJ, Musher, DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549557.CrossRefGoogle ScholarPubMed
4.Deresinski, S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2009;49:10721079.Google Scholar